Loading...
XKRX
092040
Market cap14mUSD
Jul 10, Last price  
1,215.00KRW
1D
5.19%
1Q
-36.98%
Jan 2017
-94.46%
IPO
-96.84%
Name

Amicogen Inc

Chart & Performance

D1W1MN
XKRX:092040 chart
P/E
P/S
0.57
EPS
Div Yield, %
Shrs. gr., 5y
5.99%
Rev. gr., 5y
-18.38%
Revenues
41.97b
-75.83%
23,180,942,20027,331,643,81032,457,291,97268,968,044,74473,665,135,17494,521,965,173115,180,889,376115,856,069,000124,880,967,000144,295,727,000159,904,289,000173,604,674,00041,967,749,000
Net income
-29.96b
L-43.25%
7,574,696,3207,563,006,7302,065,660,8631,588,678,628-4,605,846,38240,168,083,20686,718,41331,604,369,0003,732,651,000-47,219,841,000-23,288,916,000-52,791,135,000-29,959,566,000
CFO
-24.42b
L+83.16%
6,623,420,9804,425,691,46012,342,714,19411,276,966,40811,882,053,2712,840,022,7428,760,341,0008,865,818,0008,073,460,000-22,413,068,0008,642,675,000-13,335,193,000-24,424,733,000
Dividend
Dec 28, 2016400 KRW/sh
Earnings
Dec 14, 2026

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Amicogen, Inc. is an industrial biotechnology firm established in 2000, with its headquarters located in Jinju-si, South Korea, conducting business both domestically and globally. The company engineers and supplies a diverse range of specialized enzymes, such as CX and SP, that serve critical functions across the pharmaceutical, food, chemical, and energy sectors. In addition to enzymes, Amicogen produces innovative bio-ingredients, including N-acetylglucosamine for enhancing skin moisture and joint well-being; pinitol/D-chiro-inositol; collagen peptides and tripeptides aimed at promoting skin and general health; chitoslim and chitosan oligosaccharides; various lactic acid bacteria; as well as fucoxanthin, curezyme, food enzymes, and bamboo salt. Furthermore, the company markets its own consumer lines, K-nutra for health-related products and KeyClean for disinfectants, and also provides protein purification resins.
IPO date
Sep 12, 2013
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT